Skip to main content
. Author manuscript; available in PMC: 2017 Feb 22.
Published in final edited form as: Cancer Res. 2013 Oct 14;73(23):6913–6925. doi: 10.1158/0008-5472.CAN-13-0424

Figure 3.

Figure 3

Low expression of PIP4K2B correlates with adverse parameters of tumour progression. A. Kaplan-Meier curve showing the effect of PIP4K2B protein expression levels on event-free survival as a function of time from diagnosis until local, regional or distant metastasis or breast cancer-specific death. Low PIP4K2B expression group 1 correlated with poor patient outcome in contrast to the intermediate and high expression of PIP4K2B (groups 2 and 3), (Log Rank chi-squared = 6.753, P = 0.034).

B. Distribution of PIP4K2B gene expression was assessed across 2999 primary breast cancer tumours integrated from 17 studies. The data are presented as a frequency distribution of PIP4K2B expression. The samples were amalgamated into three groups based on PIP4K2B expression for further analysis: Top 10% (red) middle 80% (green) and the lowest 10% (blue). High expression of PIP4K2B (Red) was clearly associated with high ERBB2 expression. C. Cumulative recurrence-free outcome was plotted for low, middle and high PIP4K2B expression as defined above.